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Background: Epidermal growth factor receptor gene copy number (EGFR GCN) has been heavily investigated as a
potential predictive biomarker for the treatment of metastatic colorectal cancer (mCRC) with anti-EGFR monoclonal
antibodies (MAbs). The objective of this study was to systematically review current evidences on this issue.
Methods: PubMed, EMBASE, The Cochrane Library, Chinese Biomedical Literature Database, Wanfang Data, and the
conference abstracts of American Society of Clinical Oncology and European Society of Medical Oncology were
comprehensively searched. Studies that reported the objective response rate (ORR), progression-free survival, and/or
overall survival of mCRC patients treated with anti-EGFR MAbs, stratified by EGFR GCN status, were included. The
effect measures for binary outcome (response) and time-to-event outcomes (progression-free survival and overall
survival) were risk difference and hazard ratio, respectively. Statistical heterogeneity among the studies was assessed
by the Cochran’s Q-test and the I2 statistic. If appropriate, a quantitative synthesis of data from different studies
would be conducted with a random-effects model.
Results: Nineteen eligible studies were identified. The criteria for increased EGFR GCN (GCN+) were highly
inconsistent across different studies. The prevalence of GCN+ ranged from 6.9% to 88.9%, and the difference in ORR
between patients with GCN+ and those with non-increased EGFR GCN (GCN-) varied from −28% to 84%. Because of
the significant heterogeneity, no quantitative synthesis of data was performed. There was a general trend towards
higher ORR in patients with GCN+. The difference in ORRs between patients with GCN+ and those with GCN- was
even greater in KRAS wild-type patients, while in KRAS mutated patients the difference often did not exist. Almost
all patients with EGFR amplification responded to the treatment. However, the prevalence of EGFR amplification was
generally low. Incomplete data on progression-free survival and overall survival seemingly supported the findings
on ORR.
Conclusions: Although increased EGFR GCN is generally associated with a better outcome of anti-EGFR MAbs
treatment, especially among patients with wild-type KRAS, the clinical utility of this biomarker for selecting
recipients of anti-EGFR MAbs would be severely limited by the heterogeneous scoring system and the poor
reproducibility of EGFR GCN enumeration due to technical reasons.
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Colorectal cancer (CRC) is the third most common ma-
lignant disease and the fourth leading cause of cancer-
related deaths worldwide [1]. Synchronous metastases
have occurred in about 25% of patients at the time of
diagnosis, and an additional 40% to 50% develop second-
ary metastases during the course of their disease after
diagnosis [2]. For most patients with metastatic CRC
(mCRC), chemotherapy is traditionally the first choice.
However, the response rate is usually less than 50% [2]
and the five-year survival rate of mCRC patients remains
below 10% [3].
The chimeric IgG1 cetuximab and the fully humanized
IgG2 panitumumab, two monoclonal antibodies (MAbs)
targeted at epidermal growth factor receptor (EGFR), were
found effective in combination with chemotherapy or as a
single agent for the treatment of chemotherapy-resistant
mCRC [4-6]. However, the tumor response rate increased
by anti-EGFR MAbs was only 10%-20%, whether it be
used as the 1st- or 2nd-line treatment [4,6-9]. As anti-
EGFR MAbs were associated with significant increase in
toxicities [5] and costs [10], it is important to identify the
responsive patients for treatment and prevent non-
responsive ones from exposure to unnecessary treatment.
It has been established that KRAS mutations are a
strong predictor of resistance to anti-EGFR MAbs [11-
13]. However, a significant proportion of patients with
wild-type KRAS remain unresponsive to anti-EGFR
MAbs. Therefore, the identification of new biomarkers
that can be used jointly with KRAS has become appeal-
ing in predicting treatment response.
Moroni and colleagues reported for the first time a
strong relation between EGFR gene copy number (GCN)
and the response of patients to anti-EGFR MAbs [14].
This relation has since been substantially investigated.
However, published studies on this topic are generally
small in sample size, which may have led to inconsistent
results, and thus each study alone may not be strong
enough to produce a firm conclusion [15]. In addition,
sparse data from individual studies is available to assess
the impact of EGFR GCN on such patient-important
outcomes as progression-free survival (PFS) and overall
survival (OS) [16,17].
Therefore, we conducted a systematic review of current
evidences to assess the predictive role of an increase of
EGFR GCN in the treatment of mCRC with anti-EGFR
MAbs, with a hope to take a step further towards the ul-
timate end of personalized treatment of mCRC.
Results
Figure 1 shows the inclusion and exclusion of studies
step by step. In total, 19 eligible studies were identified
[14-32], of which 17 provided data on ORR [14-26,28-
31] and 15 on PFS or OS [15-21,24,25,27-32].Description of the studies
The basic characteristics of these studies were summar-
ized in Table 1. Most of them were retrospective studies,
with sample sizes varying from 27 to 155. Three studies
were conducted in KRAS wild-type patients only
[16,31,32], and another eight studies reported the data on
KRAS wild-type and mutant patients separately
[14,18,19,22,24-26,28], providing us the opportunity to
examine the impact of KRAS status on the predictive
power of GCN+. The anti-EGFR MAb administered, the
response criteria, and the assay for EGFR GCN quantifica-
tion were generally consistent across different studies.
However, the lines of treatment and the sources of tumor
samples used for GCN testing were relatively inconsistent.
Most notably, the criteria for GCN+were highly het-
erogeneous among different studies. In one study [26],
only gene amplification was considered as GCN+. In six
studies [15,16,22-24,30], GCN+ included both high level
of polysomy and amplification. In two studies [17,21], all
levels of polysomy and amplification were considered as
GCN+. The definitions of polysomy, high polysomy, and
amplification, respectively, also varied across studies.
The most commonly used criteria for high polysomy
and amplification were “≥ 4 gene copies in ≥ 40 % of
cells” [15,16,23,24,30] and “gene/CEP7≥ 2, or ≥ 15 gene
copies in ≥ 10% of cells” [15,23,24,30], respectively. In
seven studies [14,18-20,27,28,31], only the average gene
copies per nucleus was used to define GCN+, with the
cutoff points varying from 2.6 to 3. For two of the seven
studies [14,27] where the cutoff point was “gene copies/
nucleus ≥ 3”, GCN+ could be viewed as polysomy
according to the definition given in the study of Sartore-
Bianchi et al. [17]. Similarly, the criteria used in the
study of Tol et al. [32] was “gene copies/nucleus ≥3, or
gene/CEP7≥ 2”, which could be viewed as approximate
to “polysomy or amplification” according to the defini-
tions from the studies of Campanella et al., Sartore-
Bianchi et al., and others (Table 1).
The prevalence of GCN+ in these studies ranged from
6.9% to 88.9%, partly reflecting the significant heterogeneity
in the criteria for GCN+. Even in studies that used the same
criteria to define GCN+, the prevalence of GCN+also var-
ied considerably. For example, see the studies of Bengala
et al. and Cappuzzo et al.; the studies of Gevorgyan et al.,
Goncalves et al., Italiano et al. and Sastre et al.; the studies
of Mancuso et al. and Moroni et al.; or the studies of Per-
rone et al. and Personeni et al. (Table 1). As shown in
Table 2, the prevalence of gene amplification was generally
low, ranging from 0 to 10%, except in two studies.
The association of EGFR gene copy number status with
clinical outcomes
The ORRs stratified by EGFR GCN status were summar-
ized Figure 2. There was significant statistical heterogeneity
1636 references identified by database search:
403 Pubmed
1043 EMBASE
50 The Cochrane Library
50 Chinese Biomedical Literature Database
90 Wanfang Data
425 duplicates 
19 studies included for final analysis
1149 abstracts excluded:
677 reviews, editorials, letters, notes, etc.
472 with irrelevant patients, treatment, 
biomarker, and / or outcome
1211 abstracts screened
44 full texts excluded:
21 reviews, editorials, letters, notes, etc.
23 with irrelevant patients, treatment, 
biomarker, and/or outcome




American Society of Clinical Oncology:
10 meetings
European Society of Medical Oncology:
14 “visual meetings”
7 “other scientific meeting reports”
19 potentially eligible studies
62 full texts reviewed
Figure 1 Flow chart of study selection.
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pooled only the studies using identical criteria for GCN+,
the heterogeneity sustained. In view of this, and especially
considering the heterogeneous methodological as well
as clinical characteristics, we decided not to perform
quantitative synthesis of the studies, for it would be clin-
ically meaningless and the results would be difficult to
interpret.
The difference in ORRs between patients with GCN+
and those with GCN- varied from −28% to 84%. Visually,
there was a general trend towards higher ORR in patients
with GCN+ (Figure 2). Five studies [14,19,22,26,28] pro-
vided data on the ORR of EGFR amplified patients, which
also indicated a trend that the ORR increased with GCN
(Table 2), although the sample sizes were too small to pro-
duce a firm conclusion. Of the 22 EGFR amplified patients,
18 experienced an objective response, representing an ORR
of 82%. Among the four patients who did not respond,
three had KRAS or PIK3CA exon 20 mutations [14,22].Based on the data from 10 studies [14,16,18,19,22,24-
26,28,31], we further examined the association of EGFR
GCN status with objective response in wild-type and
mutant KRAS patients, respectively (Figure 3). Appar-
ently, the difference in ORRs between GCN+ and GCN-
patients was much greater in wild-type than in mutant
KRAS patients. Among patients with KRAS mutations,
there was usually no difference between GCN+ and
GCN- patients. The only exception is the study of Mo-
roni et al. (Figure 3), in which the sample size was quite
small, and both patients in the GCN+ group had EGFR
amplification [14].
PFS data was reported in 15 studies (Table 3), of which
13 showed a trend of longer PFS in GCN+patients than
in GCN- patients, although the difference was tested for
significance in only ten studies and was statistically sig-
nificant only in six of them. Two studies [21,29]
reported hazard ratios for the comparison of the PFS of
GCN+ versus GCN- patients, which were 0.54 (95% CI:
Table 1 Basic characteristics of the 19 eligible studies











Bengala 200925 Retrospective 55 36.5 % Cmab/Pmab; CT NA NA NA FISH
Campanella 201026 Retrospective 88 37.7 % Cmab; mixed Mixed RECIST NA FISH
Cappuzzo 200823 Retrospective 85 NA Cmab; CT ≥2nd RECIST Mixed FISH
Frattini 200727 Retrospective 27 37.0 % Cmab; CT Mixed RECIST Primary FISH
Gevorgyan 200728 Retrospective 40 NA Cmab; CT NA NA Primary FISH
Goncalves 200829 Retrospective 29 44.8 % Cmab; CT ≥2nd WHO Mixed FISH
Italiano 200815 Retrospective 41 NA Cmab; CT NA RECIST Primary FISH
Khambata-Ford 200730 Prospective 56 34.6 % Cmab; MT ≥2nd WHO Metastatic Q-PCR
Laurent-Puig 200916 Retrospective 96 0 % Cmab; CT ≥2nd RECIST Mixed FISH+CISH
Lievre 200631 Retrospective 30 43.3 % Cmab; CT ≥2nd RECIST Primary CISH
Mancuso 200832 Retrospective 31 32.3 % Cmab; NA NA NA NA FISH
Moroni 200514 Retrospective 29 31.0 % Cmab/Pmab; mixed Mixed RECIST Primary FISH
Perrone 200924 Retrospective 31 24.1 % Cmab; CT ≥2nd RECIST Mixed FISH
Personeni 200833 Retrospective 87 33.3 % Cmab; mixed ≥3rd RECIST NA FISH
Razis 200834 Retrospective 66 NA Cmab; CT ≥2nd NA Metastatic FISH
Sartore-Bianchi 200717 Retrospective 58 NA Pmab; MT ≥2nd RECIST NA FISH
Sastre 200935 Prospective 36 21.7 % Cmab; MT 1st WHO NA FISH
Scartozzi 200936 Retrospective 37 0 % Cmab; CT ≥2nd RECIST Primary FISH
Tol 201037 Retrospective 155 0 % Cmab; CT 1st RECIST Primary FISH
Study Criteria for GCN+ GCN+%
Bengala 200925 Gene copies/nucleus≥ 2.9 30.9
Campanella 201026 Polysomy: CEP7≥ 3; amplification: gene/CEP7≥ 2.0 68.2
Cappuzzo 200823 Gene copies/nucleus ≥2.92* 50.6
Frattini 200727 High polysomy: CEP7 > 4 in≥ 50 % of cells; amplification: gene/CEP7 > 3 in≥ 10 % of cells 88.9
Gevorgyan 200728 High polysomy: ≥ 4 gene copies in≥ 40 % of cells; amplification: gene clusters, gene/CEP7≥ 2, or≥
15 gene copies in≥ 10 % of cells
20.0
Goncalves 200829 High polysomy: ≥ 4 gene copies in≥ 40 % of cells and gene/CEP7≤ 2; amplification: gene/CEP7≥ 2 or≥ 15
gene copies in≥ 10 % of cells
6.9
Italiano 200815 High polysomy: ≥ 4 gene copies in≥ 40 % of cells; amplification: gene/CEP7≥ 2, or≥ 15 gene copies
in≥ 10 % of cells
19.5
Khambata-Ford 200730 NA 7.1
Laurent-Puig 200916 High polysomy: ≥ 4 gene copies in≥ 40 % of cells; amplification: gene clusters, gene/CEP7≥ 2, or≥ 10
gene copies in ≥10 % of cells
17.7
Lievre 200631 Amplification: ≥ 6 gene copies in > 50 % of cells, or gene clusters 10.0
Mancuso 200832 Gene copies/nucleus≥ 3 58.1
Moroni 200514 Gene copies/nucleus≥ 3 31.0
Perrone 200924 Gene copies/nucleus≥ 2.79* 74.2
Personeni 200833 Gene copies/nucleus≥ 2.83* 37.9
Razis 200834 gene/CEP7> 1.2 7.6
Sartore-Bianchi 200717 Polysomy: gene copies/nucleus≥ 3; amplification: gene/CEP7≥ 2; in≥ 43 % of cells 32.8
Sastre 200935 High polysomy: ≥ 4 gene copies in≥ 40 % of cells; amplification: gene/CEP7≥ 2, or≥ 15 gene copies
in≥ 10 % of cells
30.6
Scartozzi 200936 Gene copies/nucleus≥ 2.6* 40.5
Tol 201037 Gene copies/nucleus≥ 3, or gene/CEP7≥ 2 15.3
N, sample size; GCN, gene copy number; GCN+, increased gene copy number; Cmab, cetuximab; Pmab, panitumumab; CT, combination therapy; NA, not available;
RECIST, Response Evaluation Criteria in Solid Tumors; FISH, fluorescent in situ hybridization; CEP7, chromosome 7; WHO, World Health Organization criteria; MT,
monotherapy; Q-PCR, quantitative polymerase chain reaction; CISH, chromogenic in situ hybridization.
* the cutoff point was identified by Receiver Operating Characteristics analysis.
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http://www.jhoonline.org/content/5/1/520.32-0.93) and 0.82 (95% CI: 0.29-2.26), respectively,
both favoring GCN+patients. Eight studies provided
data on OS [15-18,20,28,31,32], and six of them reported
a longer OS in GCN+ than in GCN- patients, although
the difference was statistically significant in only two
studies.Publication bias
Because of the substantial heterogeneity among the
included studies, we did not conduct the test for publi-
cation bias using funnel plot, for it would probably be
misleading in this case [33,34].Discussion
This systematic review summarized the evidences on the
predictive value of EGFR GCN+ for clinical outcomes of
mCRC treated with anti-EGFR MAbs. The data we col-
lected showed that generally GCN+was associated with
a better objective response, especially among patients
with wild-type KRAS, which supports the notions that
KRAS mutations are a strong predictor of non-response
to the anti-EGFR MAbs treatment [11-13], and new bio-
markers for the treatment would be primarily useful in
KRAS wild-type patients [35].
However, the present systematic review was limited by
the following factors. First, the majority of the included
studies was retrospective in their nature, and thus might
have suffered from some important bias. Second, there
was significant heterogeneity among the studies, which
precluded a clinically meaningful meta-analysis of the
quantitative data. Third, although the PFS and OS were
seemingly longer in GCN+ than in GCN- patients, the
data on these outcomes was relatively incompleteTable 2 Prevalence and objective response rate of patients w
Study N Prevalence (positive/total)
Amplification High polysomy Other GC
Campanella 201026 88 4/88 84/88
Frattini 200727 27 8/27 16/27 3
Gevorgyan 200728 40 8/40 19/40
Gonvalves 200829 29 0/29 2/29 10/29
Italiano 200815 41 0/41 8/41 2/41
Lievre 200631 30 3/30 2
Moroni 200514* 29 7/29 2/29
Perrone 200924 31 2/31 21/31
Personeni 200833 87 2/87 31/87
Sartore-Bianchi 200717 58 0/58 58/58
Tol 201037 556 13/556 72/556
N, sample size; GCN+, increased gene copy number; GCN-, non-increased gene cop
* This study did not specify the criteria for “amplification” explicitly. We applied the
of this study.to convincingly support our conclusion on objective
response.
More importantly, current evidences suggest that the
clinical utility of EGFR GCN would be severely limited
by two major problems. First, the scoring system of
EGFR GCN has a high inter-laboratory variability, and
none of the criteria used to define GCN+universally
outperformed other criteria in terms of the discrimin-
atory power. In some studies, the cutoff point for GCN+
was identified by Receiver Operating Characteristics
analysis, but frequently a cutoff value shown to have
good sensitivity and specificity in one study performed
less well in another. For example, in the study of Cap-
puzzo et al. [18], the cutoff point “gene copies/nucleus ≥
2.92” categorized the patients into two groups in which
the ORR were 33% (14/43) and 2% (1/42), respectively,
with a sensitivity of 58.6% and a specificity of 93.3%.
However, when the cutoff value was applied to the
patients in the study of Personeni et al. [28], the corre-
sponding sensitivity and specificity were only 56.0% and
75.8%, respectively. A standard cutoff value that can be
used as a reference is yet to be established. Of note, even
in studies that used the same criteria for GCN+, there
was also significant variability in the difference of ORRs
between GCN+ and GCN- patients. For example, see
the studies of Gevorgyan et al., Goncalves et al., Italiano
et al. and Sastre et al. (Figure 2).
The criteria for EGFR gene amplification have been
relatively consistent across studies [15,16,21,24], and
patients with this molecular alteration generally had
good response to anti-EGFR MAbs. In addition, it is
readily identifiable by fluorescent in situ hybridization
(FISH) assay. However, EGFR gene amplification proved
to be a rare event, rendering it clinically less significant.ith different statuses of EGFR gene
Objective Response Rate (responder/total)
N+ GCN- Amplification High polysomy Other GCN+ GCN-
NR NR
/27 6/8 4/16 0/3
12/40 0/8 0/19 5/13
17/29 NA 2/2 3/10 4/17
31/41 NA 2/8 8/33
7/30 3/3 8/27
20/29 6/7 2/2 1/20
8/31 1/2 4/21 4/8
54/87 2/2 15/31 8/54
NA 6/58
471/556 NR NR NR NR
y number; NR, not reported; NA, not applicable.
most popular criterion (gene/CEP7 ≥ 2, see Table 1) to categorize the patients
Figure 2 Difference in objective response rate between GCN+and GCN- patients. For GCN+group, the total events and patients were 125
and 301, respectively. For GCN- group, the total events and patients were 106 and 590, respectively. Heterogeneity test: P <0.00001, I2 = 78%.
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actually harboring “polysomy” or “high polysomy”.
Whether these statuses are equal to amplification in
terms of their biological effects and especially the impact
on the response to anti-EGFR MAbs remains unclear.
Second, the enumeration of EGFR GCN suffers from
poor reproducibility. One reason for this is the within-
tumor variation [36]. For example, the mean EGFR
GCN of different sections within a tumor could be
highly heterogeneous, leading to potential misclassifica-
tion of EGFR GCN status in up to 39% of patients [28].
To a greater degree, the poor reproducibility is due to
technical factors. For example, the thickness of tumor
sections might affect the EGFR GCN detected, with
thinner sections possibly responsible for a lower GCN
cutoff value [18]. Notably, a recent international inter-Figure 3 Difference in objective response rate between GCN+and GC
KRAS, the total events and patients were 73 and 124, respectively, for GCN
Heterogeneity test: P =0.02, I2 = 54%. In patients with mutant KRAS, the tota
and were 2 and 97, respectively, for GCN- group. Heterogeneity test: P =0.0laboratory reproducibility ring study [37] conducted by
five “highly experienced molecular diagnostic centers”
showed that even under standardized conditions, the
results of FISH analysis, which was the most commonly
used method the determine EGFR GCN, could still vary
drastically from one laboratory to another. The low con-
sensus rate was proposed to be related with such tech-
nical factors as the equipment used for the analyses, the
skills necessary to perform enumeration of GCN, and
the personnel difference in interpreting the pre-specified
guidelines [37]. Although it is possible to enhance the
consensus by intensive staff training in a research set-
ting, it would be difficult to achieve this goal in routine
practice. To date, scientifically validated and widely
accepted protocol and guidelines for detecting EGFR
GCN, which have been available for non-small cell lungN- patients, stratified by KRAS status. In patients with wild-type
+ group, and were 61 and 230, respectively, for GCN- group.
l events and patients were 7 and 44, respectively, for GCN+group,
05, I2 = 70%.
Table 3 The relation of EGFR gene copy number status with progression-free survival and overall survival
Study Median PFS (mo) HR P Median OS (mo) HR P
GCN+vs GCN- GCN+vs GCN-
Bengala 200925 – – NS – – NS
Campanella 201026 – 0.54 0.03 – – –
Cappuzzo 200823 6.6 vs 3.5* – 0.02 11.3 vs 8.5* – 0.8
Goncalves 200829 4.1 vs 3.3 – – – – –
Italiano 200815 – – 0.70 – – 0.82
Khambata-Ford 200730 4.8 vs 2.0 – – – – –
Laurent-Puig 200916 7.9 vs 6.5 – 0.280 19.7 vs 13.9 – 0.180
Mancuso 200832 6.2 vs 3.2 – 0.003 – – –
Perrone 200924 6 vs 5 – – – – –
Personeni 200833 5.5 vs 4 – 0.25 10 vs 8.3 – 0.037
Razis 200834 8.7 vs 6.4-6.9* 0.82 NS – – –
Sartore-Bianchi 200717 – – 0.039 – – 0.015
Sastre 200935 4.9 vs 2.6 – 0.03 11.1 – –
Scartozzi 200936 7.7 vs 2.9 – 0.04 16 vs 9.5 – 0.2
Tol 201037 9.5 vs 10.4 – 0.19 21.9 vs 22.0 – 0.65
PFS, progression-free survival; mo, month; GCN+, increased gene copy number; GCN-, non-increased gene copy number; HR, hazard ratio; OS, overall survival; –,
not available; NS, not significant (without detailed numerical values).
* The original studies did not specify whether the number was “mean” or “median”.
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may partly explain why EGFR GCN has not yet been
incorporated into clinical practice.
Conclusions
Although increased EGFR GCN is generally associated
with a better outcome of anti-EGFR MAbs treatment, es-
pecially among patients with wild-type KRAS, the clinical
utility of this biomarker for selecting recipients of anti-
EGFR MAbs would be severely limited by the heteroge-
neous scoring system and the poor reproducibility of EGFR
GCN enumeration due to technical reasons.Methods
Literature search
We performed a systematic search of PubMed, EMBASE,
The Cochrane Library, Chinese Biomedical Literature
Database, and Wanfang Data from inception to 22 Novem-
ber 2010. The detailed search strategy was described in the
Additional file 1. Briefly, both the MeSH terms and various
text words for CRC, MAbs and EGFR were used to identify
relevant publications. The search was in the end limited to
“human studies”. In the light of the results of our pilot
search, we did not include the terms related to the bio-
marker (i.e. “gene copy number”) and concerned outcomes
(e.g., “objective response” and “overall survival”) in the final
search strategy so as to increase the search sensitivity. In
addition to searching the above electronic databases, we
also tried to identify eligible studies from the conference
abstracts of American Society of Clinical Oncology andEuropean Society of Medical Oncology via their official
websites. All potentially relevant studies were retrieved and
their references were scrutinized for further relevant
publications.
Study selection
All “potentially eligible” studies were reviewed independ-
ently and then agreed on their eligibility by two
reviewers. Studies that met all of the following four cri-
teria were considered eligible for this review: 1) patients:
mCRC; 2) treatment: MAbs as monotherapy or in com-
bination with other agents for treatment of any lines; 3)
biomarker: EGFR GCN; and 4) outcomes: one or more
of the following outcomes stratified by EGFR GCN sta-
tus: objective response (the sum of complete response
and partial response), PFS, and OS. Although PFS theor-
etically differs from time-to-progression, the two out-
comes were often used interchangeably in existing
clinical cancer research. Therefore, we did not distin-
guish them in this meta-analysis, but used PFS alone to
denote either of the two. When the same patient popula-
tion was used in more than one publication, only the
one with most relevant data was included in this review.
Disagreements between the two reviewers were resolved
by discussion. Unsettled disagreements which were few
were referred to the “third wise man” for final verdict.
Data extraction
The following data were collected from each eligible
study: first author’s name, year of publication, study de-
sign, total number of patients eligible to be included in
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patients with increased EGFR GCN (GCN+) (stratified
by KRAS mutation status, if applicable), number of
patients with non-increased GCN (GCN-) (stratified by
KRAS mutation status, if applicable), line of treatment,
treatment regimen, response criteria, original location of
tumor tissues used for analysis, method for EGFR GCN
analysis, criteria for “GCN+”, objective response rate
(ORR), PFS, OS, and hazard ratio for the comparison of
PFS/OS. Data on ORR, PFS, and OS were extracted sep-
arately according to EGFR GCN status (further accord-
ing to KRAS mutation status, if applicable).
With respect to the line of treatment, we pragmatically
categorized a study as “1st-line” if ≥ 90% of the patients
received 1st-line MAbs treatment. Similarly, a study was
considered as “≥ 2nd-line” if ≥ 90% of the patients
received 2nd-line or higher anti-EGFR MAbs treatment.
All other studies were categorized as “mixed”. The same
principle was applied to “treatment regimen” (monother-
apy vs combined-therapy vs mixed) and “original loca-
tion of tumor tissues used for analysis” (primary vs
metastatic vs mixed).
If any key data (e.g. the number of patients responsive
to anti-EGFR MAbs by EGFR GCN status) was absent in
the original paper, authors were contacted by e-mail for
relevant information.
Statistical methods
The outcomes of interest included objective response,
PFS, and OS. The impact of EGFR GCN status on ob-
jective response was measured by risk difference, which
was the ORR of patients with GCN+ subtracted by that
of patients with GCN-. The association of EGFR GCN
status with PFS or OS was denoted by hazard ratio. A
hazard ratio equal to one means no difference between
the compared groups. A hazard ratio less than one indi-
cates that the risk for disease progression or death was
lower in patients with GCN+ than in those with GCN-,
i.e. the PFS or OS of patients with GCN+was longer
than that of patients with GCN-, and vice versa.
The statistical heterogeneity among studies was
assessed by the Cochran’s Q-test [39,40] and the I2 stat-
istic [40,41]. A P value ≤ 0.10 for the Q-test or an
I2 > 50% was suggestive of substantial between-study het-
erogeneity. The clinical and methodological characteris-
tics of the eligible studies were also examined to see if a
quantitative synthesis of the collected data was appropri-
ate. If not, then the data was summarized and presented
in a descriptive manner; if yes, then the risk differences
and hazard ratios respectively from different studies
were combined by using a random-effects model (DerSi-
monian and Laird method) [41,42]. Further meta-
analyses of risk difference and/or hazard ratio, stratified
by KRAS status, would be performed wherever possible.If appropriate and data allowed us to do so, pre-
specified subgroup analyses were conducted to explore
the source of the heterogeneity according to treatment
regimen, line of treatment, response criteria, original lo-
cation of tumor tissues used for analysis, method for
EGFR GCN analysis, and the cutoff value for GCN+.
Egger’s funnel plot was planned to be used to assess the
possibility of publication bias as appropriate [43]. All
statistical analyses were performed in RevMan 5.0.
Additional file
Additional file 1: Detailed search strategy. This document describes
the search strategy in details.
Abbreviations
CEP7: chromosome 7; EGFR: epidermal growth factor receptor; GCN: gene
copy number; GCN+: increased epidermal growth factor receptor gene copy
number; GCN-: non-increased epidermal growth factor receptor gene copy
number; mCRC: metastatic colorectal cancer; MAbs: monoclonal antibodies;
PFS: progression-free survival; ORR: objective response rate; OS: overall
survival.
Competing interests
The authors have declared no conflicts of interest.
Authors’ contributions
ZYY, WXS, CM, and JLT designed the systematic review; ZYY, WXS, XFH, DYZ,
XYW, YFH, JZC, and CM were involved in the literature search and study
selection; ZYY, XFH, XYW, YFH, and CM extracted the data from eligible
studies; ZYY and CM conducted the analysis; ZYY, WXS, DYZ, JZC, CM, and
JLT were involved in the interpretation of the results. ZYY, WXS, CM, and JLT
were responsible for the writing and critical revisions of the manuscript. All
authors read and approved the final manuscript.
Author details
1Division of Epidemiology, the Jockey Club School of Public Health and
Primary Care, the Chinese University of Hong Kong, Hong Kong, People’s
Republic of China. 2Cancer Institute, the Second Clinical Medical College,
Jinan University, Shenzhen People's Hospital, Shenzhen, Guangdong
Province, People’s Republic of China. 3Department of Oncology, Nanfang
Hospital, Southern Medical University, Guangzhou, Guangdong Province,
People’s Republic of China.
Received: 21 June 2012 Accepted: 17 July 2012
Published: 16 August 2012
References
1. GLOBOCAN: Cancer fact sheet. 2008 http://globocan.iarc.fr/factsheets/
cancers/colorectal.asp#INCIDENCE1.
2. Meyerhardt JA, Mayer RJ: Systemic therapy for colorectal cancer. N Engl J
Med 2005, 352:476–487.
3. Sargent DJ, Wieand HS, Haller DG, et al: Disease-free survival versus overall
survival as a primary end point for adjuvant colon cancer studies:
individual patient data from 20,898 patients on 18 randomized trials.
J Clin Oncol 2005, 23:8664–8670.
4. Bokemeyer C, Bondarenko I, Makhson A, et al: Fluorouracil, leucovorin, and
oxaliplatin with and without cetuximab in the first-line treatment of
metastatic colorectal cancer. J Clin Oncol 2009, 27:663–671.
5. Tol J, Punt CJ: Monoclonal antibodies in the treatment of metastatic
colorectal cancer: a review. Clin Ther 2010, 32:437–453.
6. Van Cutsem E, Köhne CH, Hitre E, et al: Cetuximab and chemotherapy as
initial treatment for metastatic colorectal cancer. N Engl J Med 2009,
360:1408–1417.
7. Sobrero AF, Maurel J, Fehrenbacher L, et al: EPIC: phase III trial of
cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure
Yang et al. Journal of Hematology & Oncology 2012, 5:52 Page 9 of 9
http://www.jhoonline.org/content/5/1/52in patients with metastatic colorectal cancer. J Clin Oncol 2008,
26:2311–2319.
8. Peeters M, Price TJ, Cervantes A, et al: Randomized phase III study of
panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI)
compared with FOLFIRI alone as second-line treatment in patients with
metastatic colorectal cancer. J Clin Oncol 2010, 28:4706–4713.
9. Douillard JY, Siena S, Cassidy J, et al: Randomized, phase III trial of
panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin
(FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with
previously untreated metastatic colorectal cancer: the PRIME study. J Clin
Oncol 2010, 28:4697–4705.
10. Schrag D: The Price Tag on Progress — Chemotherapy for Colorectal
Cancer. N Engl J Med 2004, 351:317–319.
11. Dahabreh IJ, Terasawa T, Castaldi PJ, et al: Systematic review:
Anti-epidermal growth factor receptor treatment effect modification by
KRAS mutations in advanced colorectal cancer. Ann Intern Med 2011,
154:37–49.
12. Linardou H, Dahabreh IJ, Kanaloupiti D, et al: Assessment of somatic k-RAS
mutations as a mechanism associated with resistance to EGFR-targeted
agents: a systematic review and metaanalysis of studies in advanced
non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol
2008, 9:962–972.
13. Qiu LX, Mao C, Zhang J, et al: Predictive and prognostic value of KRAS
mutations in metastatic colorectal cancer patients treated with
cetuximab: a meta-analysis of 22 studies. Eur J Cancer 2010, 46:2781–2787.
14. Moroni M, Veronese S, Benvenuti S, et al: Gene copy number for
epidermal growth factor receptor (EGFR) and clinical response to
antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol
2005, 6:279–286.
15. Italiano A, Follana P, Caroli FX, et al: Cetuximab shows activity in colorectal
cancer patients with tumors for which FISH analysis does not detect an
increase in EGFR gene copy number. Ann Surg Oncol 2008, 15:649–654.
16. Laurent-Puig P, Cayre A, Manceau G, et al: Analysis of PTEN, BRAF, and
EGFR status in determining benefit from cetuximab therapy in wild-type
KRAS metastatic colon cancer. J Clin Oncol 2009, 27:5924–5930.
17. Sartore-Bianchi A, Moroni M, Veronese S, et al: Epidermal growth factor
receptor gene copy number and clinical outcome of metastatic
colorectal cancer treated with panitumumab. J Clin Oncol 2007,
25:3238–3245.
18. Cappuzzo F, Finocchiaro G, Rossi E, et al: EGFR FISH assay predicts for
response to cetuximab in chemotherapy refractory colorectal cancer
patients. Ann Oncol 2008, 19:717–723.
19. Perrone F, Lampis A, Orsenigo M, et al: PI3KCA/PTEN deregulation
contributes to impaired responses to cetuximab in metastatic colorectal
cancer patients. Ann Oncol 2009, 20:84–90.
20. Bengala C, Bettelli S, Fontana A, et al: EGFR gene copy number, KRAS and
BRAF status, PTEN and AKT expression analysis in patients with
metastatic colon cancer treated with anti-EGFR monoclonal antibodies ±
chemotherapy [abstract]. J Clin Oncol 2009, 27:15055.
21. Campanella C, Mottolese M, Cianciulli A, et al: Epidermal growth factor
receptor gene copy number in 101 advanced colorectal cancer patients
treated with chemotherapy plus cetuximab. J Transl Med 2010,
8:36–43.
22. Frattini M, Saletti P, Romagnani E, et al: PTEN loss of expression predicts
cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer
2007, 97:1139–1145.
23. Gevorgyan A, Di Bartolomeo M, Andreola S, et al: Epidermal Growth Factor
Receptor (EGFr) status detection in correlation to objective response on
cetuximab-based therapy in patients (pts) with advanced colorectal
cancer (ACC) [abstract]. In: 2007 ASCO Annual Meeting Proceedings Part
I. J Clin Oncol 2007, 25(18):21070.
24. Goncalves A, Esteyries S, Taylor-Smedra B, et al: A polymorphism of EGFR
extracellular domain is associated with progression free-survival in
metastatic colorectal cancer patients receiving cetuximab-based
treatment. BMC Cancer 2008, 8:169–179.
25. Khambata-Ford S, Garrett CR, Meropol NJ, et al: Expression of epiregulin
and amphiregulin and K-ras mutation status predict disease control in
metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol
2007, 25:3230–3237.26. Lievre A, Bachet JB, Le Corre D, et al: KRAS mutation status is predictive of
response to cetuximab therapy in colorectal cancer. Cancer Res 2006,
66:3992–3995.
27. Mancuso A, Leone A, Vigna L, et al: EGFR, DCC, and K-RAS mutations as
predictive factors for cetuximab sensitivity in metastatic colorectal
cancer (mCRC) [abstract]. J Clin Oncol 2008, 26(20):4128.
28. Personeni N, Fieuws S, Piessevaux H, et al: Clinical usefulness of EGFR gene
copy number as a predictive marker in colorectal cancer patients
treated with cetuximab:a fluorescent in situ hybridization study.
Clin Cancer Res 2008, 14:5869–5876.
29. Razis E, Briasoulis E, Vrettou E, et al: Potential value of PTEN in predicting
cetuximab response in colorectal cancer:an exploratory study. BMC
Cancer 2008, 8:234–243.
30. Sastre J, Aranda E, Grávalos C, et al: First-line single-agent cetuximab in
elderly patients with metastatic colorectal cancer. A phase II clinical and
molecular study of the Spanish group for digestive tumor therapy (TTD).
Crit Rev Oncol Hematol 2011, 77:78–84. Epub 2009 Dec 29.
31. Scartozzi M, Bearzi I, Mandolesi A, et al: Epidermal Growth Factor Receptor
(EGFR) gene copy number (GCN) correlates with clinical activity of
irinotecan-cetuximab in K-RAS wild-type colorectal cancer:a fluorescence
in situ (FISH) and chromogenic in situ hybridization (CISH) analysis.
BMC Cancer 2009, 9:303–311.
32. Tol J, Dijkstra JR, Klomp M, et al: Markers for EGFR pathway activation as
predictor of outcome in metastatic colorectal cancer patients treated
with or without cetuximab. Eur J Cancer 2010, 46:1997–2009.
33. Lau J, Ioannidis JP, Terrin N, Schmid CH, Olkin I: The case of the misleading
funnel plot. BMJ 2006, 333:597–600.
34. Tang JL, Liu JL: Misleading funnel plot for detection of bias in meta-
analysis. J Clin Epidemiol 2000, 53:477–84.
35. Mao C, Yang ZY, Hu XF, et al: PIK3CA exon 20 mutations as a potential
biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS
wild-type metastatic colorectal cancer:a systematic review and meta-
analysis. Ann Oncol 2012, 23:1518–1525.
36. Ooi A, Takehana T, Li X, et al: Protein overexpression and gene
amplification of HER-2 and EGFR in colorectal cancers:an
immunohistochemical and fluorescent in situ hybridization study. Mod
Pathol 2004, 17:895–904.
37. Sartore-Bianchi A, Fieuws S, Veronese S, et al: Standardisation of EGFR FISH
in colorectal cancer:results of an international interlaboratory
reproducibility ring study. J Clin Pathol 2012,
65:218–223.
38. Varella-Garcia M, Diebold J, Eberhard DA, et al: EGFR fluorescence in situ
hybridisation assay:guidelines for application to non-small-cell lung
cancer. J Clin Pathol 2009, 62:970–977.
39. Cochran WG: The combination of estimates from different experiments.
Biometrics 1954, 10:101–129.
40. Higgins JPT, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency
in meta-analyses. BMJ 2003, 327:557–560.
41. Deeks JJ, Higgins JPT, Altman DG: Analysing and presenting results.
Chichester, UK: John Wiley & Sons, Ltd: In: Higgins JPT, Green S, editors.
Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated
September 2006], Section 8; 2006:4.
42. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials
1986, 7:177–188.
43. Egger M, Smith DG, Schneider M, Minder C: Bias in meta-analysis detected
by a simple, graphical test. BMJ 1997, 315:629–634.
doi:10.1186/1756-8722-5-52
Cite this article as: Yang et al.: EGFR gene copy number as a predictive
biomarker for the treatment of metastatic colorectal cancer with anti-
EGFR monoclonal antibodies: a meta-analysis. Journal of Hematology &
Oncology 2012 5:52.
